Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$83,357.00+2.27%ETH$2,457.93+2.99%GOLD$4,144.50+0.05%OIL$99.78+2.00%
Smart Investors Daily
SID Premium
AD

NASDAQ · ADAG

Adagene Inc.

Healthcare · Biotechnology

$2.50

Up+$0.21 (+9.17%)

Updated Oct 21, 2026, 10:29 AM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
111.61M
P/E ratio
-2.9
Dividend yield
0.00%
52-week range
$1.30 – $4.85
Volume
92.71K
Avg. volume
119.56K

Price performance · ADAG

ADAG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 20, 2026

ADAG closed at $2.50 after 21 trading sessions, down 22.60% for the selected period.

Last close
$2.50
Period change
-22.60%
Period low
$2.06
Period high
$3.23
Daily close
View OHLC price history
ADAG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 20, 2026$2.30$2.50$2.30$2.5092.71K
Oct 19, 2026$2.04$2.29$2.01$2.29308.8K
Oct 16, 2026$2.40$2.40$2.01$2.06379.6K
Oct 15, 2026$2.31$2.42$2.26$2.40552.48K
Oct 14, 2026$2.35$2.50$2.25$2.29898.86K
Oct 13, 2026$2.73$2.73$2.435$2.46228.89K
Oct 12, 2026$2.77$2.8554$2.68$2.74216.5K
Oct 9, 2026$2.76$2.87$2.625$2.761.65M
Oct 8, 2026$2.80$3.10$2.71$2.78240.47K
Oct 7, 2026$2.90$3.1019$2.785$2.81173.07K
Oct 6, 2026$2.82$3.02$2.82$2.93213.52K
Oct 5, 2026$2.84$2.87$2.67$2.80325.71K
Oct 2, 2026$2.96$3.00$2.80$2.85297.97K
Oct 1, 2026$3.12$3.12$2.915$2.93278.28K
Sep 30, 2026$3.18$3.35$3.00$3.20254.32K
Sep 29, 2026$3.20$3.47$2.98$3.21492.59K
Sep 28, 2026$2.94$3.21$2.87$3.20529.85K
Sep 25, 2026$2.96$3.185$2.87$2.93197.66K
Sep 24, 2026$2.94$3.01$2.81$2.98317.09K
Sep 23, 2026$3.16$3.22$2.92$2.97208.02K
Sep 22, 2026$3.31$3.3379$3.215$3.23226.33K

Latest ADAG news

The latest Smart Investors Daily articles mentioning ADAG.

Stock researchCompany · Overview

ADAG research

Overview

Company profile and research snapshot.

Company profile

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.00
Implied upside
—
Analysts
14
ADAG recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
Sep 14, 2026HC Wainwright & Co.Buy—
Sep 10, 2026Chardan CapitalBuy—
Apr 6, 2026GuggenheimBuy—
Nov 24, 2025GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference being held virtually on October 15, 2026. H.C. Wainwright 4th Annual I

Yahoo · Sep 22, 2026

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By